Clinical pharmacology in adolescent transgender medicine.
adolescents
clinical pharmacology
hormone
puberty
transgender
Journal
British journal of clinical pharmacology
ISSN: 1365-2125
Titre abrégé: Br J Clin Pharmacol
Pays: England
ID NLM: 7503323
Informations de publication
Date de publication:
26 Aug 2024
26 Aug 2024
Historique:
revised:
18
07
2024
received:
09
02
2024
accepted:
19
07
2024
medline:
27
8
2024
pubmed:
27
8
2024
entrez:
26
8
2024
Statut:
aheadofprint
Résumé
Adolescent transgender medicine is a growing clinical field. Gender-affirming medications for transgender youth may include gonadotropin-releasing hormone (GnRH) agonists, gender-affirming hormones or both. To evaluate the potential effects of GnRH agonists (puberty suppression) on pharmacokinetic processes for transgender youth, we searched PubMed from inception to May 2024 for publications on the effects of GnRH agonists on drug absorption, distribution, metabolism or excretion for transgender adolescents or effects on hormones (including gonadotropins, adrenal androgens, sex steroids) that are associated with changes in drug metabolism during puberty in the general adolescent population. No publications discussed the effects of GnRH agonist treatment on pharmacokinetic processes for adolescent transgender people. Sixteen publications observed marked decreases in gonadotropins and sex steroids for both adolescent transgender men and adolescent transgender women and slight effects on adrenal androgens. During GnRH agonist treatment, changes in body composition and body shape were greater for adolescent transgender people than for cisgender adolescent people. Further research is needed to better understand the effects of GnRH agonists on drug metabolism and other pharmacokinetic processes for transgender adolescents receiving GnRH agonists and other gender-affirming medications.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIGMS NIH HHS
ID : K23GM147350
Pays : United States
Organisme : NIH HHS
Pays : United States
Informations de copyright
© 2024 The Author(s). British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Références
Coleman E, Radix A, Bouman W, et al. Standards of Care for the Health of transgender and gender diverse people, version 8. Int J Transgender Health. 2022;23(sup1):S1‐S259. doi:10.1080/26895269.2022.2100644
Hembree WC, Cohen‐Kettenis PT, Gooren L, et al. Endocrine treatment of gender‐dysphoric/gender‐incongruent persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2017;102(11):3869‐3903. doi:10.1210/jc.2017‐01658
Clark TC, Lucassen MF, Bullen P, et al. The health and well‐being of transgender high school students: results from the New Zealand adolescent health survey (Youth'12). J Adolesc Health. 2014;55(1):93‐99. doi:10.1016/j.jadohealth.2013.11.008
Johns MM, Lowry R, Andrzejewski J, et al. Transgender identity and experiences of violence victimization, substance use, suicide risk, and sexual risk behaviors among high school students—19 states and large urban school districts, 2017. Morb Mortal Wkly Rep. 2019;68(3):67‐71. doi:10.15585/mmwr.mm6803a3
Becker I, Ravens‐Sieberer U, Ottová‐Jordan V, Schulte‐Markwort M. Prevalence of adolescent gender experiences and gender expression in Germany. J Adolesc Health. 2017;61(1):83‐90. doi:10.1016/j.jadohealth.2017.02.001
van der Loos M, Klink DT, Hannema SE, et al. Children and adolescents in the Amsterdam cohort of gender dysphoria: trends in diagnostic‐ and treatment trajectories during the first 20 years of the Dutch protocol. J Sex Med. 2023;20(3):398‐409. doi:10.1093/jsxmed/qdac029
Wiepjes CM, Nota NM, de Blok CJM, et al. The Amsterdam cohort of gender dysphoria study (1972–2015): trends in prevalence, treatment, and regrets. J Sex Med. 2018;15(4):582‐590. doi:10.1016/j.jsxm.2018.01.016
Olson‐Kennedy J, Chan Y‐M, Garofalo R, et al. Impact of early medical treatment for transgender youth: protocol for the longitudinal, observational trans youth care study. JMIR Res Protocols. 2019;8(7):e14434. doi:10.2196/14434
Boogers LS, Wiepjes CM, Staphorsius AS, et al. A European network for the investigation of gender incongruence in adolescents. J Sex Med. 2024;21(4):350‐356. doi:10.1093/jsxmed/qdae014
Ramos GGF, Mengai ACS, Daltro CAT, Cutrim PT, Zlotnik E, Beck APA. Systematic review: puberty suppression with GnRH analogues in adolescents with gender incongruity. J Endocrinol Invest. 2021;44(6):1151‐1158. doi:10.1007/s40618‐020‐01449‐5
Thompson L, Sarovic D, Wilson P, et al. A PRISMA systematic review of adolescent gender dysphoria literature: (3) treatment. PLOS Global Public Health. 2023;3(8):e0001478. doi:10.1371/journal.pgph.0001478
Ludvigsson JF, Adolfsson J, Höistad M, Rydelius P‐A, Kriström B, Landén M. A systematic review of hormone treatment for children with gender dysphoria and recommendations for research. Acta Paediatr. 2023;112(11):2279‐2292. doi:10.1111/apa.16791
Klaver M, de Mutsert R, Wiepjes CM, et al. Early hormonal treatment affects body composition and body shape in young transgender adolescents. J Sex Med. 2018;15(2):251‐260. doi:10.1016/j.jsxm.2017.12.009
Olson‐Kennedy J, Chan Y‐M, Rosenthal S, et al. Creating the trans youth research network: a collaborative research endeavor. Transgender Health. 2019;4(1):304‐312. doi:10.1089/trgh.2019.0024
Chen D, Berona J, Chan YM, et al. Psychosocial functioning in transgender youth after 2 years of hormones. N Engl J Med. 2023;388(3):240‐250. doi:10.1056/NEJMoa2206297
Scheim AI, Baker KE, Restar AJ, Sell RL. Health and health care among transgender adults in the United States. Annu Rev Public Health. 2022;43(1):503‐523. doi:10.1146/annurev‐publhealth‐052620‐100313
Sequeira GM, Boyer T, Coulter RWS, Miller E, Kahn NF, Ray KN. Healthcare experiences of gender diverse youth across clinical settings. J Pediatr. 2022;240:251‐255. doi:10.1016/j.jpeds.2021.08.089
Boyer TL, Sequeira GM, Egan JE, Ray KN, Miller E, Coulter RWS. Binary and nonbinary transgender Adolescents' healthcare experiences, avoidance, and well visits. J Adolesc Health. 2022;71(4):438‐445. doi:10.1016/j.jadohealth.2022.04.016
Delozier AM, Kamody RC, Rodgers S, Chen D. Health disparities in transgender and gender expansive adolescents: a topical review from a minority stress framework. J Pediatr Psychol. 2020;45(8):842‐847. doi:10.1093/jpepsy/jsaa040
Reisner SL, Greytak EA, Parsons JT, Ybarra ML. Gender minority social stress in adolescence: disparities in adolescent bullying and substance use by gender identity. J Sex Res. 2015;52(3):243‐256. doi:10.1080/00224499.2014.886321
Veale JF, Watson RJ, Peter T, Saewyc EM. Mental health disparities among Canadian transgender youth. J Adolesc Health. 2017;60(1):44‐49. doi:10.1016/j.jadohealth.2016.09.014
Becerra‐Culqui TA, Liu Y, Nash R, et al. Mental health of transgender and gender nonconforming youth compared with their peers. Pediatrics. 2018;141(5):e20173845. doi:10.1542/peds.2017‐3845
Rich AJ, Scheim AI, Koehoorn M, Poteat T. Non‐HIV chronic disease burden among transgender populations globally: a systematic review and narrative synthesis. Prev Med Rep. 2020;20:101259. doi:10.1016/j.pmedr.2020.101259
Reisner SL, Vetters R, Leclerc M, et al. Mental health of transgender youth in care at an adolescent urban community health center: a matched retrospective cohort study. J Adolesc Health. 2015;56(3):274‐279. doi:10.1016/j.jadohealth.2014.10.264
Baral SD, Poteat T, Stromdahl S, Wirtz AL, Guadamuz TE, Beyrer C. Worldwide burden of HIV in transgender women: a systematic review and meta‐analysis. Lancet Infect Dis. 2013;13(3):214‐222. doi:10.1016/S1473‐3099(12)70315‐8
Stutterheim SE, van Dijk M, Wang H, Jonas KJ. The worldwide burden of HIV in transgender individuals: an updated systematic review and meta‐analysis. PLoS ONE. 2021;16(12):e0260063. doi:10.1371/journal.pone.0260063
Andrzejewski J, Dunville R, Johns MM, Michaels S, Reisner SL. Medical gender affirmation and HIV and sexually transmitted disease prevention in transgender youth: results from the survey of Today's adolescent relationships and transitions, 2018. LGBT Health. 2021;8(3):181‐189. doi:10.1089/Lgbt.2020.0367
Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV epidemic: a plan for the United States. Jama. 2019;321(9):844‐845. doi:10.1001/jama.2019.1343
Hales CM, Kit BK, Gu Q, Ogden CL. Trends in prescription medication use among children and adolescents‐United States, 1999‐2014. Jama. 2018;319(19):2009‐2020. doi:10.1001/jama.2018.5690
Centers for Disease Control and Prevention. CDC NHANES—National Health and nutrition examination survey homepage. 2024; Retrieved from: https://wwwn.cdc.gov/nchs/nhanes/Default.aspx Accessed 1 Feb 2024.
Hisle‐Gorman E, Schvey NA, Adirim TA, et al. Mental healthcare utilization of transgender youth before and after affirming treatment. J Sex Med. 2021;18(8):1444‐1454. doi:10.1016/j.jsxm.2021.05.014
T'Sjoen G, Radix A, Motmans J. Language & Ethics in transgender health. J Sex Med. 2020;17(9):1585‐1586. doi:10.1016/j.jsxm.2020.05.017
Kennedy MJ. Hormonal regulation of hepatic drug‐metabolizing enzyme activity during adolescence. Clin Pharmacol Ther. 2008;84(6):662‐673. doi:10.1038/clpt.2008.202
Le A, Huang KJ, Cirrincione LR. Regulation of drug‐metabolizing enzymes by sex‐related hormones: clinical implications for transgender medicine. Trends Pharmacol Sci. 2022;43(7):582‐592. doi:10.1016/j.tips.2022.03.006
Cirrincione LR, Huang KJ. Sex and gender differences in clinical pharmacology: implications for transgender medicine. Clin Pharmacol Ther. 2021;110(4):897‐908. doi:10.1002/cpt.2234
Finkelstein JW. The effect of developmental changes in adolescence on drug disposition. J Adolesc Health. 1994;15(8):612‐618. doi:10.1016/S1054‐139X(94)90627‐0
Kearns GL, van den Anker JN. Adolescents and drug development: commentary on a dawning paradigm shift. J Clin Pharmacol. 2021;61(6):740‐743. doi:10.1002/jcph.1862
Carr RR, Ensom MH. Drug disposition and therapy in adolescence: the effects of puberty. J Pediatr Pharmacol Ther. 2003;8(2):86‐96. doi:10.5863/1551‐6776‐8.2.86
Martinerie L, Condat A, Bargiacchi A, Bremont‐Weill C, de Vries MC, Hannema SE. MANAGEMENT OF ENDOCRINE DISEASE: approach to the management of children and adolescents with gender dysphoria. Eur J Endocrinol. 2018;179:R219‐R237.
Salas‐Humara C, Sequeira GM, Rossi W, Dhar CP. Gender affirming medical care of transgender youth. Curr Probl Pediatr Adolesc Health Care. 2019;49(9):100683. doi:10.1016/j.cppeds.2019.100683
Lee JY, Rosenthal SM. Gender‐affirming Care of Transgender and Gender‐Diverse Youth: current concepts. Annu Rev Med. 2023;74(1):107‐116. doi:10.1146/annurev‐med‐043021‐032007
Mahfouda S, Moore JK, Siafarikas A, et al. Gender‐affirming hormones and surgery in transgender children and adolescents. Lancet Diabetes Endocrinol. 2019;7(6):484‐498. doi:10.1016/S2213‐8587(18)30305‐X
Lahlou N, Carel JC, Chaussain JL, Roger M. Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metab. 2000;13(Suppl 1):723‐737. doi:10.1515/JPEM.2000.13.S1.723
Schulmeister C, Millington K, Kaufman M, et al. Growth in transgender/gender‐diverse youth in the first year of treatment with gonadotropin‐releasing hormone agonists. J Adolesc Health. 2022;70(1):108‐113. doi:10.1016/j.jadohealth.2021.06.022
Olson‐Kennedy J, Streeter LH, Garofalo R, Chan YM, Rosenthal SM. Histrelin implants for suppression of puberty in youth with gender dysphoria: a comparison of 50 mcg/day (Vantas) and 65 mcg/day (SupprelinLA). Transgend Health. 2021;6(1):36‐42. doi:10.1089/trgh.2020.0055
Eitel KB, Hodax JK, DiVall S, Kidd KM, Salehi P, Sequeira GM. Leuprolide acetate for puberty suppression in transgender and gender diverse youth: a comparison of subcutaneous Eligard versus intramuscular Lupron. J Adolesc Health. 2023;72(2):307‐311. doi:10.1016/j.jadohealth.2022.09.017
Schagen SE, Cohen‐Kettenis PT, Delemarre‐van de Waal HA, Hannema SE. Efficacy and safety of gonadotropin‐releasing hormone agonist treatment to suppress puberty in gender dysphoric adolescents. J Sex Med. 2016;13(7):1125‐1132. doi:10.1016/j.jsxm.2016.05.004
Cirrincione LR, Senneker T, Scarsi K, Tseng A. Drug interactions with gender‐affirming hormone therapy: focus on antiretrovirals and direct acting antivirals. Expert Opin Drug Metab Toxicol. 2020;16(7):565‐581. doi:10.1080/17425255.2020.1777278
Defreyne J, Vanwonterghem Y, Collet S, et al. Vaginal bleeding and spotting in transgender men after initiation of testosterone therapy: a prospective cohort study (ENIGI). Int J Transgend Health. 2020;21(2):163‐175. doi:10.1080/26895269.2020.1719951
Rafferty J, Yogman M, Baum R, et al. Ensuring comprehensive care and support for transgender and gender‐diverse children and adolescents. Pediatrics. 2018;142(4):e20182162. doi:10.1542/peds.2018‐2162
Grimstad F, Kremen J, Shim J, Charlton BM, Boskey ER. Breakthrough bleeding in transgender and gender diverse adolescents and young adults on long‐term testosterone. J Pediatr Adolesc Gynecol. 2021;34(5):706‐716. doi:10.1016/j.jpag.2021.04.004
Yager J, Brooks KM, Brothers J, et al. Pharmacokinetics of emtricitabine/tenofovir disoproxil fumarate among transgender adolescents and young adults without HIV receiving gender affirming hormones. AIDS Res Hum Retroviruses. 2022;38(11):840‐846. doi:10.1089/aid.2022.0043
Yager J, Brooks KM, Brothers J, et al. Gender‐affirming hormone pharmacokinetics among adolescent and young adult transgender persons receiving daily emtricitabine/tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses. 2022;38(12):939‐943. doi:10.1089/aid.2022.0044
Perl L, Elkon‐Tamir E, Segev‐Becker A, Israeli G, Brener A, Oren A. Blood pressure dynamics after pubertal suppression with gonadotropin‐releasing hormone analogs followed by estradiol treatment in transgender female adolescents: a pilot study. J Pediatric Endocrinol Metabolism/J Pediatric Endocrinol Metabolism. 2021;34(6):741‐745. doi:10.1515/jpem‐2021‐0172
Boogers LS, Wiepjes CM, Klink DT, et al. Transgender girls grow tall: adult height is unaffected by GnRH analogue and estradiol treatment. J Clin Endocrinol Metab. 2022;107(9):e3805‐e3815. doi:10.1210/clinem/dgac349
Stoffers IE, de Vries MC, Hannema SE. Physical changes, laboratory parameters, and bone mineral density during testosterone treatment in adolescents with gender dysphoria. J Sex Med. 2019;16(9):1459‐1468. doi:10.1016/j.jsxm.2019.06.014
Willemsen LA, Boogers LS, Wiepjes CM, et al. Just as tall on testosterone; a neutral to positive effect on adult height of GnRHa and testosterone in trans boys. J Clin Endocrinol Metab. 2023;108(2):414‐421. doi:10.1210/clinem/dgac571
Pine‐Twaddell E, Newfield RS, Marinkovic M. Extended use of Histrelin implant in pediatric patients. Transgend Health. 2023;8(3):264‐272. doi:10.1089/trgh.2021.0130
Schagen SEE, Lustenhouwer P, Cohen‐Kettenis PT, Delemarre‐van de Waal HA, Hannema SE. Changes in adrenal androgens during puberty suppression and gender‐affirming hormone treatment in adolescents with gender dysphoria. J Sex Med. 2018;15(9):1357‐1363. doi:10.1016/j.jsxm.2018.07.017
Fisher AD, Ristori J, Romani A, et al. Back to the future: is GnRHa treatment in transgender and gender diverse adolescents only an extended evaluation phase? J Clin Endocrinol Metabol. 2024;109(6):1565‐1579. doi:10.1210/clinem/dgad729
Karakilic Ozturan E, Ozturk A, Bas F, et al. Endocrinological approach to adolescents with gender dysphoria: experience of a pediatric endocrinology department in a tertiary center in Turkey. J Clin Res Pediatr Endocrinol. 2023;15(4):15. doi:10.4274/jcrpe.galenos.2023.2023‐9‐20
Mejia‐Otero JD, White P, Lopez X. Effectiveness of puberty suppression with gonadotropin‐releasing hormone agonists in transgender youth. Transgend Health. 2021;6(1):31‐35. doi:10.1089/trgh.2020.0007
Klink D, Caris M, Heijboer A, van Trotsenburg M, Rotteveel J. Bone mass in young adulthood following gonadotropin‐releasing hormone analog treatment and cross‐sex hormone treatment in adolescents with gender dysphoria. J Clin Endocrinol Metabol. 2015;100(2):E270‐E275. doi:10.1210/jc.2014‐2439
Norup PB, Haahr ME, Christiansen P, et al. Growth and adult height attainment in Danish transgender adolescents treated with GnRH analog and sex hormones. J Clin Endocrinol Metab. Published online April 17, 2024. doi:10.1210/clinem/dgae263
Perl L, Segev‐Becker A, Israeli G, Elkon‐Tamir E, Oren A. Blood pressure dynamics after pubertal suppression with gonadotropin‐releasing hormone analogs followed by testosterone treatment in transgender male adolescents: a pilot study. LGBT Health. 2020;7(6):340‐344. doi:10.1089/Lgbt.2020.0026
Kearns GL, Abdel‐Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology — drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157‐1167. doi:10.1056/NEJMra035092
Anderson GD, Lynn AM. Optimizing pediatric dosing: a developmental pharmacologic approach. Pharmacotherapy: the journal of human pharmacology and drug. Therapy. 2009;29(6):680‐690. doi:10.1592/phco.29.6.680
Strolin Benedetti M, Baltes E. Drug metabolism and disposition in children. Fundam Clin Pharmacol. 2003;17(3):281‐299. doi:10.1046/j.1472‐8206.2003.00140.x
Bartelink IH, Rademaker CM, Schobben AF, Van Den Anker JN. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet. 2006;45(11):1077‐1097. doi:10.2165/00003088‐200645110‐00003
van den Anker JN, Schwab M, Kearns GL. Developmental pharmacokinetics. Handb Exp Pharmacol. 2011;51‐75. doi:10.1007/978‐3‐642‐20195‐0_2
Vinarov Z, Abdallah M, Agundez JAG, et al. Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: an UNGAP review. Eur J Pharm Sci. 2021;162:105812. doi:10.1016/j.ejps.2021.105812
Batchelor HK, Marriott JF. Paediatric pharmacokinetics: key considerations. Br J Clin Pharmacol. 2015;79(3):395‐404. doi:10.1111/bcp.12267
Kuczmarski RJ. 2000 CDC growth charts for the United States: methods and development: Department of Health and Human Services, centers for disease control and …; 2002.
Bomberg EM, Miller BS, Addo OY, Rogol AD, Jaber MM, Sarafoglou K. Sex non‐specific growth charts and potential clinical implications in the care of transgender youth. Front Endocrinol (Lausanne). 2023;14:1227886. doi:10.3389/fendo.2023.1227886
Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005;352(21):2211‐2221. doi:10.1056/NEJMra032424
de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet. 1999;37(6):485‐505. doi:10.2165/00003088‐199937060‐00004
Suzuki Y, Cox S, Hayes J, Walson PD. Carbamazepine age‐dose ratio relationship in children. Ther Drug Monit. 1991;13(3):201‐208. doi:10.1097/00007691‐199105000‐00003
Albani F, Riva R, Contin M, Baruzzi A. A within‐subject analysis of carbamazepine disposition related to development in children with epilepsy. Ther Drug Monit. 1992;14(6):457‐460. doi:10.1097/00007691‐199212000‐00003
Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103‐141. doi:10.1016/j.pharmthera.2012.12.007
Lambert GH, Schoeller DA, Kotake AN, Flores C, Hay D. The effect of age, gender, and sexual maturation on the caffeine breath test. Dev Pharmacol Ther. 1986;9(6):375‐388. doi:10.1159/000457262
Almeida M, Laurent MR, Dubois V, et al. Estrogens and androgens in skeletal physiology and pathophysiology. Physiol Rev. 2016;97(1):135‐187. doi:10.1152/physrev.00033.2015
Martha PM Jr, Rogol AD, Veldhuis JD, Kerrigan JR, Goodman DW, Blizzard RM. Alterations in the pulsatile properties of circulating growth hormone concentrations during puberty in boys. J Clin Endocrinol Metab. 1989;69(3):563‐570. doi:10.1210/jcem‐69‐3‐563
Krupka E, Curtis S, Ferguson T, et al. The effect of gender‐affirming hormone therapy on measures of kidney function: a systematic review and meta‐analysis. Clin J Am Soc Nephrol. 2022;17(9):1305‐1315. doi:10.2215/CJN.01890222
Millington K, Barrera E, Daga A, et al. The effect of gender‐affirming hormone treatment on serum creatinine in transgender and gender‐diverse youth: implications for estimating GFR. Pediatr Nephrol. 2022;37(9):2141‐2150. doi:10.1007/s00467‐022‐05445‐0
Pierce CB, Muñoz A, Ng DK, Warady BA, Furth SL, Schwartz GJ. Age‐ and sex‐dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease. Kidney Int. 2021;99(4):948‐956. doi:10.1016/j.kint.2020.10.047
Inker LA, Eneanya ND, Coresh J, et al. New creatinine‐and cystatin C–based equations to estimate GFR without race. N Engl J Med. 2021;385(19):1737‐1749. doi:10.1056/NEJMoa2102953
Turino Miranda K, Greene DN, Collister D, et al. A holistic framework for the evaluation of kidney function in a gender‐diverse landscape. Am J Kidney Dis. 2024;84(2):232‐240. doi:10.1053/j.ajkd.2024.01.522
Asquith A, Sava L, Harris AB, Radix AE, Pardee DJ, Reisner SL. Patient‐centered practices for engaging transgender and gender diverse patients in clinical research studies. BMC Med Res Methodol. 2021;21(1):1‐15. doi:10.1186/s12874‐021‐01328‐4
Owen‐Smith AA, Woodyatt C, Sineath RC, et al. Perceptions of barriers to and facilitators of participation in Health Research among transgender people. Transgend Health. 2016;1:187‐196. doi:10.1089/trgh.2016.0023